AR453588

Cat. No.:	HY-133127		
CAS No.:	1065609-00-8		
Molecular Formula:	C ₂₅ H ₂₅ N ₇ O ₂ S ₂		
Molecular Weight:	519.64		
Target:	Glucokinase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (192.44 mM; Need ultrasonic)						
Preparing Stock Solutions	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	1.9244 mL	9.6220 mL	19.2441 mL		
	5 mM	0.3849 mL	1.9244 mL	3.8488 mL			
	10 mM	0.1924 mL	0.9622 mL	1.9244 mL			
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent o Solubility: ≥ 2.5 m	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution						

DIOLOGICALACIN					
Description	AR453588 is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC ₅₀ of 42 nM. AR453588 shows anti-hyperglycemic activity ^[1] .				
In Vivo	AR453588 (3-30 mg/kg; p.o) lowers post-prandial glucose in normal C57BL/6J mice ^[1] . AR453588 (3-30 mg/kg; p.o.; once-daily for 14 days) shows anti-hyperglycemic activity in a dose-ranging 14 day ob/ob mouse ^[1] . AR453588 (10 mg/kg; p.o.) treatment shows that the T _{max} , AUC _{inf} , Vss, C _{max} and F are 1.0 mL/min/kg, 4.65 h μg /mL, 1.67 μg				

RedChemExpress



Product Data Sheet

/mL and 60.3%, respectively ^[] AR453588 (1 mg/kg; i.v.) treat 1.28 hours, respectively ^[1] . MCE has not independently co	$^{1]}$ ment shows that the CL, AUC _{inf} , Vss, and $t_{1/2}$ are 21.6 mL/min/kg, 0.77 h μ g /mL, 0.746 L/kg and onfirmed the accuracy of these methods. They are for reference only.
Animal Model:	Male diabetic ob/ob mice $^{[1]}$
Dosage:	3, 10, 30 mg/kg
Administration:	Orally once-daily for 14 days
Result:	Lowered the fasted blood glucose from the control animals on day 14 as well as the AUC of the OGTT (oral glucose tolerance tests).
Animal Model:	Male CD-1 mice ^[1]
Dosage:	10 mg/kg
Administration:	p.o. (Pharmacokinetic Analysis)
Result:	The $T_{max},$ AUC $_{inf},$ Vss, C_{max} and F were 1.0 mL/min/kg, 4.65 h μg /mL, 1.67 μg /mL and 60.3%, respectively.

REFERENCES

[1]. Hinklin RJ, et al. Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator. Bioorg Med Chem. 2020 Jan 1;28(1):115232.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA